Genus Lifesciences Company Profile

✉ Email this page to a colleague

GENUS LIFESCIENCES has seven approved drugs.

There are nineteen US patents protecting GENUS LIFESCIENCES drugs.

There are forty-four patent family members on GENUS LIFESCIENCES drugs in twenty-three countries and twenty-six supplementary protection certificates in thirteen countries.

International Patents:	44
US Patents:	19
Tradenames:	6
Ingredients:	6
NDAs:	7
Patent Litigation for Genus Lifesciences:	See patent lawsuits for Genus Lifesciences

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016		DISCN	Yes	No	9,539,214	See Plans and Pricing				See Plans and Pricing
Genus Lifesciences	LEVETIRACETAM	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	204754-002	Aug 26, 2016	AB	RX	No	No		See Plans and Pricing				See Plans and Pricing
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016		DISCN	Yes	No	9,987,231	See Plans and Pricing				See Plans and Pricing
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016		DISCN	Yes	No	9,539,214	See Plans and Pricing				See Plans and Pricing
Genus Lifesciences	POTASSIUM CHLORIDE	potassium chloride	SOLUTION;ORAL	206814-001	Dec 22, 2014	AA	RX	Yes	No		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	81 mg/40 mg	➤ Subscribe	2016-10-14

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration
Mexico	2014007935	See Plans and Pricing
Japan	2004536809	See Plans and Pricing
European Patent Office	2797600	See Plans and Pricing
Eurasian Patent Organization	200301321	See Plans and Pricing
South Africa	201102645	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try it Free
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	18/2011	Austria	See Plans and Pricing	PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105
1411900	132012902015795	Italy	See Plans and Pricing	PRODUCT NAME: NAPROSSENE E ESOMEPRAZOLO SALE DI MAGNESIO TRIIDRATO(VIMOVO); AUTHORISATION NUMBER(S) AND DATE(S): PL 17901/0263-0001, 20101105;DA 40611016/M A 40611129/M, 20110808
1411900	122012000052	Germany	See Plans and Pricing	PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0480717	98C0025	Belgium	See Plans and Pricing	PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0253310	SPC/GB95/010	United Kingdom	See Plans and Pricing	PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.